pipeline-prospector-insert-v1
X

Find Approved Gastroenterology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fosnetupitant Chloride,Palonosetron

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Helsinn Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Linaclotide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Teva Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 23, 2020

            Details:

            Pursuant to the terms of the settlement, Ironwood and Allergan will grant Teva a license to market its 145 mcg and 290 mcg generic version of LINZESS in U.S.

            Contract Sales Organization

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Triethanolamine Salicylate

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tetra Bio-Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 20, 2020

            Details:

            Tetra is finalizing a commercial supply agreement and initiating activities to secure private reimbursement for the two TERPACANâ„¢ products.